Grifols on track to meet 2024 targets as core earnings rise
Adds EBITDA, targets, short-seller context
MADRID, Nov 7 (Reuters) -Spanish drugmaker Grifols <GRLS.MC> said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago but its core earnings rose 27%.
The company, which focuses on human plasma-based drugs, booked a net profit of 52 million euros ($56.11 million) in the period on revenues worth 1.79 billion euros, up 12%.
Analysts polled by LSEG expected revenues of 1.75 billion euros during the period.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in the first nine months of the year rose 24% to 1.25 billion euros. Nine-month revenues rose nearly 9% year-on-year.
Grifols had said it expected revenues to rise more than 7% this year and EBITDA to surpass 1.8 billion euros.
Canadian fund Brookfield BN.TO together with the Grifols family are in the process of taking over the company with a view to potentially delisting it.
The company has lost around 30% of its market value since January, when Gotham City Research, a short-seller fund, has released multiple reports accusing Grifols of overstating earnings and understating debt, which Grifols denies.
Spain's stock market regulator CNMV said in September it was sanctioning Gotham City for allegedly manipulating the market for Grifols shares, and the pharma group for some defective financial reporting.
($1 = 0.9267 euros)
Reporting by Inti Landauro, editing by Andrei Khalip
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
